Investors and Media

Investor Relations

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases. We use our transformative vector discovery platform, termed Therapeutic Vector Evolution, to create customized and proprietary gene delivery vehicles (i.e. vectors) to deliver therapeutic payloads to specific tissue types associated with the underlying disease via the optimal route of administration. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies.

4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines. 4DMT is striving to unlock the full potential of genetic medicines using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately ONE BILLION synthetic capsid sequences to invent targeted and evolved vectors for use in our products. Learn more about our pipeline HERE.

Latest Corporate Presentation

Data Provided by Refinitiv. Minimum 15 minutes delayed.